Replies to post #52526 on Biotech Values

[DewDiligence]

FDA Overwhelmed by Generic Applications



Source: Washington Post (#msg-9563839)

[DewDiligence]

>What's the status for user fees for generics?<

I’ve seen no discussion of this since the subject was broached in the press several months ago. The person to ask is probably BI.

[Biopharm investor]

Biowatch, re: generic user fees

This is a foregone conclusion. The only question is what the generic firms will get in return for paying these fees.